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ABSTRACT: A library of cholesterol-derived ionic copolymers were previously synthesized via reversible addition−fragmentation chain
transfer (RAFT) polymerization as ‘smart’ gene delivery vehicles that hold diverse surface charges. Polyplex systems formed with anionic
poly(methacrylic acid-co-cholesteryl methacrylate) (P(MAA-co-CMA)) and cationic poly(dimethylamino ethyl methacrylate-co-
cholesteryl methacrylate) (Q-P(DMAEMA-co-CMA)) copolymer series were evaluated for their therapeutic efficiency. Cell viability
assays, conducted on SHEP, HepG2, H460, and MRC5 cell lines, revealed that alterations in the copolymer composition (CMA mol %)
affected the cytotoxicity profile. Increasing the number of cholesterol moieties in Q-P(DMAEMA-co-CMA) copolymers reduced the
overall toxicity (in H460 and HepG2 cells) while P(MAA-co-CMA) series displayed no significant toxicity regardless of the CMA content.
Agarose gel electrophoresis was employed to investigate the formation of stable polyplexes and determine their complete conjugation
ratios. P(MAA-co-CMA) copolymer series were conjugated to DNA through a cationic linker, oligolysine, while Q-P(DMAEMA-co-
CMA)-siRNA complexes were readily formed via electrostatic interactions at conjugation ratios beginning from 6:1:1 (oligolysine-
P(MAA-co-CMA)-DNA) and 20:1 (Q-P(DMAEMA-co-CMA)-siRNA), respectively. The hydrodynamic diameter, ζ potential and
complex stability of the polyplexes were evaluated in accordance to complexation ratios and copolymer composition by dynamic light
scattering (DLS). The therapeutic efficiency of the conjugates was assessed in SHEP cells via transfection and imaging assays using RT-
qPCR, Western blotting, flow cytometry, and confocal microscopy. DNA transfection studies revealed P(MAA-co-CMA)-oligolysine-
DNA ternary complexes to be ineffective transfection vehicles that mostly adhere to the cell surface as opposed to internalizing and
partaking in endosomal disrupting activity. The transfection efficiency of Q-P(DMAEMA-co-CMA)-GFP siRNA complexes were found
to be polymer composition and N/P ratio dependent, with Q-2% CMA-GFP siRNA polyplexes at N/P ratio 20:1 showing the highest
gene suppression in GFP expressing SHEP cells. Cellular internalization studies suggested that Q-P(DMAEMA-co-CMA)-siRNA
conjugates efficiently escaped the endolysosomal pathway and released siRNA into the cytoplasm. The gene delivery profile, reported
herein, illuminates the positive and negative attributes of each therapeutic design and strongly suggests Q-P(DMAEMA-co-CMA)-siRNA
particles are extremely promising candidates for in vivo applications of siRNA therapy.
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■ INTRODUCTION
Gene therapy, a promising approach for the treatment of viral
infections, cancers, cardiovascular and neurodegenerative
diseases1,2 is governed by the efficiency and safety of the gene
carrier.3 Nonviral gene delivery systems, for instance, polymers,
offer several advantages over viral vectors, such as less
immunogenicity, larger gene-loading capacity and lower
cost,4−7 making them ideal candidates for gene therapy.
Most therapeutic strategies rely on the distribution of their
therapeutic materials reaching the intracellular sites at effective
concentrations while protecting the therapeutic from nuclease
degradation.8,9 One of the main obstacles that these systems
encounter is the cellular membrane transport barrier.10
Therapeutic systems are expected to efficiently destabilize the
cell membrane and facilitate the delivery of their cargo to the
cytosol and/or nucleus. Upon external stimulation, such as
acidification in the endosomal environment, ‘smart’ pH-responsive
polymers are able to change their conformation from an expanded
hydrophilic coil (at physiological pH) to a relatively less hydrophilic
globule (at acidic pH) and destabilize/disrupt the phospholipid cell
membrane.11 Owing to their membrane disrupting properties, pH-
responsive polymers have been widely investigated as therapeutic
delivery systems.12−15 A number of carboxylated amphiphatic
polymers such as poly(ethyl acrylic acid) (PEAA),16 poly(propyl
acrylic acid) (PPAA),9,13 poly(butyl acrylic acid) (PBAA),14
poly(acrylic acid/ethyl acrylate) (P(AA/EA)),9 poly(acrylic acid/
propyl acrylate) (P(AA/PA)),13 poly(methacrylic acid/butyl
acrylate) (P(MAA/BA)),8 poly(methacrylic acid/N-isopropyl
acrylamide/octadecyl acrylate) (P(MAA/NIPAA/ODA)),17 and
poly(methacrylic acid/butyl acrylate/pyridyldisulfide acrylate)
(P(MAA/BA/PDSA))8 have been described to reorganize the
lipid bilayer of membranes in a pH-dependent manner. Endosomal
membrane-disrupting polyanions have been investigated as gene
delivery agents in the form of ternary polyplexes, where the anionic
components are brought together by a cationic molecule, achieving
promising results.18−20
A different approach to escape the endosomal barrier and
enable cytosolic delivery of genes is through the use of cationic
polymers. Certain cationic polymers stimulate membrane
destabilization by a mechanism called the ‘proton-sponge
effect’,21 where the high buffering capacity of polycations leads
to increase in pH of the endosomes, accumulating ions within
this compartment, and causing osmotic swelling that eventually
bursts the vesicle.22 Polycations spontaneously interact with
negatively charged therapeutic entities, such as siRNA or DNA,
and form polyelectrolyte complexes, also known as polyplexes.23
However, for efficient gene complexation, polycations are
required to carry high charge densities along with high molecular
weights, which often causes carrier-induced toxicity and
undesired aggregation.24 Utilizing biodegradable/reducible
polycations (such as poly(β-amino ester)s, poly(spermine)s,
poly(amido amine)s),25 incorporating hydrophobic moieties,26
altering the polymer properties with poly-(ethylene glycol)
(PEG) conjugation27 are some of the common strategies
employed to lower the cytotoxicity and enhance the stability of
polyplexes.28−30
The aim of this study is to biologically evaluate the intracellular
gene delivery performance of CMA-derived ionic copolymer
seriesP(MAA-co-CMA) (as pH-responsive anionic polymer
series) and Q-P(DMAEMA-co-CMA) (as stimuli responsive
cationic polymer series)in cancer cell lines and normal cells.
Considering the ability of cholesterol to cross cellular membranes,
cholesterol units were separately fused with PMAA, to switch the
cell-membrane activity of cholesterol on or off in a pH-dependent
manner, and PDMAEMA polymers, to reduce the overall toxicity
caused by the tertiary amines, in order to provide site-selective
membrane destabilization activity in endosomes/lysosomes and
cytosolic-release of the therapeutic load. Gene transfection activity
of polymer−gene complexes were investigated using in vitro
cultured human neuroblastoma SHEP cells (cells that stably
express green fluorescent protein (GFP) were utilized in siRNA
delivery, while GFP expressing (pmaxFP-GreenC) plasmids were
transfected in non-GFP SHEP cells). The influence of the
macromolecular structureespecially variances in surface charge
and polymer composition (CMA ratio)on gene complexation
ratios and the biochemical properties of the resulting polyplexes
were examined in detail. The physicochemical properties of
complexes; specifically their transfection efficiency, endosomolytic
activity and intracellular delivery profiles were assessed in relation
to the copolymer series.
■ EXPERIMENTAL SECTION
Materials. The procedure for the RAFT-mediated polymerizations
of anionic P(MAA-co-CMA) (A-2% CMA, cholesterol content 2 mol %,
with number average molecular weight (Mn)GPC of 16500 g/mol and
polydispersity index (PDI) of 1.19; A-4% CMA, cholesterol content 4
mol %, with (Mn)GPC 15800 g/mol and PDI 1.10; A-8% CMA,
cholesterol content 8 mol %, with (Mn)GPC 18000 g/mol and PDI 1.11)
copolymer series has been previously described.31 The preparation of
quarternized-P(DMAEMA-co-CMA) copolymer series with varying
CMA units (Q-2% CMA, cholesterol content 2 mol %, with (Mn)GPC
23400 g/mol and PDI 1.13; Q-4% CMA, cholesterol content 4 mol %,
with (Mn)GPC 24800 g/mol and PDI 1.15; Q-8% CMA, cholesterol
content 8 mol %, with (Mn)GPC 19200 g/mol and PDI 1.14; Q-15%
CMA, cholesterol content 15 mol %, with (Mn)GPC 21400 g/mol and
PDI 1.16; Q-20% CMA, cholesterol content 20 mol %, with (Mn)GPC
16000 g/mol and PDI 1.17) is presented in Supporting Information
(Figure S1 and Table S1). Dulbecco’s Modified Eagle Medium
(DMEM) with 4.5 g/L glucose and L-glutamine, Roswell ParkMemorial
Institute (RPMI) medium with HEPES and L-glutamine, heat
inactivated Fetal Calf Serum (FCS), trypsin solution (0.25% (w/v)
trypsin in Hank’s solution), Trypan Blue, Opti-MEM I Reduced Serum
Medium, Lipofectamine 2000 and Geneticin were purchased from
Invitrogen Life Technologies. In vivo custom antienhanced green
fluorescence protein (anti-GFP) siRNA (sense strand; 5′-GCAAG-
CUGACCCUGAAGUUCAU-3′; antisense, 5′-GAACUUCAG-
GGUCAGCUUGCCG-3′) (14100 g/mol) was synthesized by Thermo
Scientific Dharmacon. pmaxFP-GreenC was obtained from Lonza and
TUBB-pREP4 plasmid (13.1 kb) was generated in the CCIA
laboratories. AlexaFlour488 conjugated siRNA and β2 microglubin
(β2M) primer mixes (forward + reverse) were obtained from Qiagen.
High Capasity cDNA Reverse Transcription Kit (200 Reactions) and
SYBR green kit were purchased fromApplied Biosystems. Methyl iodide
(Sigma), phosphate buffered saline (PBS; Sigma), oligolysine (1300 g/mol;
Mimotopes), protease inhibitor 100x (Roche), forward and reverse GFP
primers (Sigma Genosys), bicinchoninic acid (BCA) protein assay kit
(Pierce), and ECL plus Western Blotting Detection System was purchased
from GE Healthcare. Antiglyceraldehyde-3-phosphate dehydrogenase
(GAPDH; clone 6C5) antibody (AbCam Ltd.), GFP Rabbit Antibody
(Cell Signaling Technology), polyclonal goat antimouse immunoglobulin/
HRP and polyclonal goat antirabbit immunoglobulin/HRP were obtained
from Dako.
Instruments. Nuclear Magnetic Resonance (NMR) Spectroscopy.
1H NMR spectra were measured using a Bruker DPX 300 MHz
spectrometer. Deuterated water (D2O; Cambridge Isotope Laboratories)
was used as the solvent for solution state NMR analyses.
Gel Permeation Chromatography. Gel permeation chromatog-
raphy (GPC) was performed using N,N-dimethylacetamide (DMAc;
0.03% w/v LiBr, 0.05% w/v 2,6-dibutyl-4-methylphenol (BHT); Sigma-
Aldrich) as the mobile phase. Polymer solutions (3−5 mg/mL in
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DMAc) were injected into GPC at 40 °C (flow rate =1 mL/min).
A Shimadzu modular system comprising an SIL-10AD autoinjector, a
PL 5.0-mm bead-size guard column (50mm× 7.8 mm) followed by four
linear PL (Styragel) columns (105, 104, 103, and 100 Å) was used.
Calibration was achieved with commercial polystyrene standards
ranging from 500 to 106 g/mol. The calibration curve, acquired by the
Mark−Houwink equation, was utilized for determining the relative
molecular weight of polymers by relating their retention time (in same
mobile phase) to the molecular weight of the reference standards.
Dynamic Light Scattering. Dynamic light-scattering (DLS) studies
and ζ-potential measurements were performed using a Malvern
Zetasizer NaNo ZS Instrument (Malvern, USA) equipped with a
4 mV He-Ne laser operating at λ = 633 nm, an avalanche photodiode
detector with high quantum efficiency, and an ALV/LSE-5003 multiple
tau digital correlator electronics system. Size measurements were
performed in Disposable Solvent Resistant Micro Cuvettes ZEN0040
(Malvern Instruments) recorded in nanometers (nm) while charge
readings were conducted in Folded Capillary Cells DTS1060 (Malvern
Instruments) shown in millivolts (mV). The polyplex solutions were
prepared with appropriate buffers where particle concentrations of
0.25 mg/mL DNA (for P(MAA-co-CMA) series) and 15 μM of siRNA
(for Q-P(DMAEMA-co-CMA) series) were employed. Size and stability
measurements were conducted at 37 °C, while surface charge
investigations were performed at 25 °C. All samples were measured
by scanning seven times with each time of automatic measurement. Size
and ζ analyses were performed in triplicates while stability measure-
ments were conducted in duplicates.
Methods. Cell Culture and Toxicity. Human neuroblastoma SHEP
cells, human liver hepatocellular carcinoma (HepG2) cells, human non-
small-cell lung cancer (NSCLC) H460 cells, and human fetal lung
fibroblast (MRC5) cells were utilized to assess polymer toxicity. H460
cells were grown in Roswell Park Memorial Institute (RPMI) medium
with HEPES and L-glutamine, while SHEP, HepG2 andMRC5 cell lines
were grown in Dulbecco’s Modified Eagle Medium (DMEM)
containing 4.5 g/L glucose and L-glutamine, both media were
supplemented with 10% Fetal Calf Serum (FCS). All cells were cultured
at 37 °C in a 95% humidified atmosphere of 5% CO2. For the cell
viability assay, cells were seeded in 96-well sterile flat-bottom plates
(appropriate number of cells needed for each well was determined from
growth curves) and incubated for 24 h to ensure adherence. Upon
surface attachment cells were treated with polymer solutions at varying
concentrations and were further incubated for 72 h. After the incubation
period, 20 μL of AlamarBlue32 was added to each well, and incubated for
another 6 h. Absorbance was measured by a Benchmark Plus Microplate
Spectrophotometer at 570 nm. The percentage of viability was
expressed as a function of positive control cells (cells only in media)
representing 100% viability. The treatments were done with five
replicates and the assay was independently repeated three times.
Polyelectrolyte Complex Formation and Characterization. The
gene binding ability of both P(MAA-co-CMA) and Q-P(DMAEMA-co-
CMA) copolymer series was evaluated by agarose gel electrophoresis.
P(MAA-co-CMA)/DNA complexes were formed on the basis of
electrostatic interactions between oligolysine (amine; N), DNA
(phosphate; P) and P(MAA-co-CMA) (carboxylate; C). The charge
ratio (wt %) between P(MAA-co-CMA) and DNA was set to 1:1 (C/P;
50 ng) in PBS (0.01 M), and the N ratio was altered from 0.5 to 50 (25
ng to 2.5 μg oligolysine) throughout the study. Particle preparation
included complexing the oligolysine to DNA (50 ng, 2 μL) first
incubating for 15 min then adding P(MAA-co-CMA) (50 ng, 5 μL) to
the mixture and incubating further for 15 min with continuous shaking
on a rotary shaker. The total volume of ternary samples was made up to
15 μL using PBS. Q-P(DMAEMA-co-CMA)/siRNA complexes with
varying N/P ratios were prepared spontaneously in pH 5.0 buffer
(0.01 M) solutions. Particles were formulated according to the mole
ratio between amine (Q-P(DMAEMA-co-CMA)) and phosphate
(siRNA) groups where they were incubated for 30 min. 0.8% and 2%
agarose gels containing GelRed Nucleic Acid Stain 10,000× in water
(Biotium) were casted prior to electrophoresis to investigate DNA and
siRNA complexation, respectively. 2.5 μL of 5x DNA Loading Buffer,
Blue (BioLine), was added to each sample before they were loaded on to
the gel. As reference points, a ladder (HyperLadder II or EasyLadder II
(Bioline)), a naked gene sample, and a naked polymer sample were
included in the gel. Electrophoresis took place in Tris-borate-EDTA
(TBE) buffer (BioRad), for 1.5 h at 80 V and 1 h at 60 V for DNA and
siRNA conjugation studies, respectively. Complete complexation was
visualized by a BioRad UV Transilluminator (model No: Universal
Hood II) and imaged with a Quantity One Gel Doc XR software
program. Particle size, stability and charge studies were performed on a
Malvern Zetasizer NaNo ZS Instrument.
Gene Transfection. To investigate the transfection efficiency of
polymers, DNA and siRNA complexes were formulated and delivered
into SHEP and green fluorescent protein (GFP)-expressing SHEP cells
(GFP-SHEP), respectively. GFP-SHEP cells were maintained in
antibiotic-treated DMEM (Geneticin 14 μL/mL) medium comple-
mented with 10% FCS. Antibiotic treatments were removed and
replaced with fresh media before performing experiments on the GFP-
expressing cell lines. SHEP cells were seeded in 6-well plates (100 × 103
cells/well for SHEP; 60 × 103 cells/well for GFP-SHEP) and incubated
for 24 h prior to the treatments. Transfection media (Opti-MEM)
comprising the polymers and their conjugated therapeutics were
prepared at various N/P ratios and concentrations. One hour after
complex formation, treatments were added into the plates and seeded
with cells for 5 h. As reference points were positive controls: gene
complexes prepared with a commercially available transfection agent
Lipofectamine 2000 (L2K), along with negative control experiments:
Opti-MEM only, gene only, and L2K only (mock-transfected) were
included. After 5 h the transfection medium was replaced with DMEM
(10% FCS) media and further incubated for 48−72 h (depending on the
analysis technique) at 37 °C in 5%CO2 and 95% humidity. GFPmRNA,
protein and fluorescence intensity levels were assessed using real-time
quantitative PCR (RT-qPCR), Western blotting, and flow cytometry
(FACSCanto; Becton-Dickinson).
GFP mRNA Analysis via Real-Time Quantitative PCR. Expression of
GFP mRNA in GFP-SHEP cells was examined using RT-qPCR. Total
RNA isolations were performed as previously described.33,34 The RT-
qPCR was performed using the Applied Biosystems high-capacity
cDNA reverse transcription and SYBR green kits. Data was normalized
to the house keeping gene, β2-microglobulin (β2M), by coamplifying
both sequences in the same reaction and analyzing their real-time PCR
amplification using the ABI PRISM 7900 Sequence Detection System
(Applied Biosystems). The gene-specific primers employed for PCR
amplification are listed in Supporting Information (Table S2). All
experiments were conducted in triplicate.
GFP Protein Analysis via Western Blotting. Cellular protein was
isolated from cell pellets by solubilizing on ice in radio-immunopreci-
pitation assay (RIPA) buffer containing protease inhibitors. Equal
amounts of protein (10 μg) were loaded onto freshly prepared 10%
SDS-PAGE gels and transferred to nitrocellulose membranes. Protein
expression of GFP and loading control GAPDH were determined as
previously described.34 The experiments were repeated in triplicate with
protein isolated from three independent extractions.
Fluorescence Microscopy Imaging. SHEP cells (5000−7000 cells/
dish) were plated in 35 mm cultured dishes which were precoated with
DBL poly-D-lysine hydrobromide (Sigma) for 5 min. After 72 h of
surface adherence, cells were transfected with either P(MAA-co-CMA)-
oligolysine-TUBB-pREP4 plasmid complexes or Q-P(DMAEMA-co-
CMA)-AlexaFlour488 conjugated siRNA complexes for 5 h at 37 °C.
Transfected cells were rinsed with PBS and then stained with the
appropriate nuclear dye; 5 μMDRAQ5 (Cell Signaling Technology) or
5 μg/mL bisBenzimide H 33342 trihydrochloride (Hoescht 33342,
Sigma-Aldrich) for 5 min. Two types of confocal microscopes, Zeiss
LSM 780 and Leica TCS SP5, were used to capture the images. Controls
included fluorescently tagged genes alone, genes complexed to L2K, and
Opti-MEM treated samples.
■ RESULTS AND DISCUSSION
Determination of Cell Viability via AlamarBlue Assay.
AlamarBlue cell viability assay was employed to determine the
toxicity profile of the cholesterol-derived ionic copolymers on
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various human cell lines. The assay is based on the ability of
metabolically active cells to convert the redox dye resazurin into the
end product, resorufin, which is easily detected via fluorescence or
absorbance spectrophotometric readers.35 The viability of SHEP,
HepG2,H460 andMRC5 cells was assessed as a function of P(MAA-
co-CMA) (Figure 1) and Q-P(DMAEMA-co-CMA) (Figure 2)
treatments at varying concentrations (0.005−50 μM).
Overall the anionic copolymers (A-2% CMA, A-4% CMA, A-
8% CMA, and P(MAA)) demonstrated lower toxicity results
than those reported for poly-L-lysine (10000 g/mol,36 12000 g/mol,37
25000 g/mol38) in HepG2 and A2780 carcinoma cell lines. The
viability of the cells for 50 μM to 0.05 μM treatments varied
between 86% and 100%, indicating that these copolymers display
no major toxicity, which is in agreement with previous reports
regarding anionic polymer toxicity.8,12,39 The half-maximal
inhibitory concentration (IC50) doses of the anionic copolymers
were not calculated due to their exceptionally low toxicity values in
the concentration range studied.
In comparison to the anionic copolymers, between 50 μM and
0.05 μM treatments, Q-P(DMAEMA-co-CMA) copolymer
series displayed higher levels of cytotoxicity owing to their
cationic nature. Polymer treatments below 5 μM concentration
displayed toxicity results comparable with those of various other
cationic polymers.26,37 As anticipated, the incorporation of hydro-
phobic moieties (for Q-15% CMA and Q-20% CMA) reduced the
toxicity effect of the copolymers at higher concentrations (5 μM) in
HepG2 and H460 carcinoma cell lines. The IC50 values of
Q-P(DMAEMA-co-CMA) copolymer series illustrated in Table S3
(Supporting Information), suggest that compositions with 2%, 4%,
and 8%CMA units display higher IC50 values than those reported for
commercially available jetPEI (0.3 to 1.3 μM in HeLa cells).40
Q-P(DMAEMA-co-CMA) formulations with 15% and 20% CMA
showed IC50 values of 5.0 and 9.0 μM in HepG2 cells and 2.9 and
6.0 μM in H460 cells, respectively. The overall toxicity profile of this
library permits further in vitro studies to be conducted in these cell
lines.
Formation of Polyelectrolyte Complexes. The library of
CMA-derived ionic copolymerswas utilized to form stable polyplexes
with nucleic acids via electrostatic interactions (Scheme 1). Agarose
gel electrophoresis was employed to determine the complete
conjugation ratios of both P(MAA-co-CMA) (weight ratio) and
Q-P(DMAEMA-co-CMA) (molar ratio) based complexes. The
strong anionic nature of P(MAA-co-CMA) series prohibited
complexation with negatively charged nucleic acids. Therefore, a
cationic linker, oligolysine, was introduced into the mixture to
form stable delivery complexes that integrated both of the
negatively charged components. Oligolysine, a short chain lysine
polymer with 10 repeating units, was selected due to its efficient
condensing ability to nucleotides and its low toxicity profile.41 In
addition to playing a pivotal role in assembling the entire complex,
oligolysine could possibly increase the overall transfection
efficiency of the complex.42,43
An initial study was conducted on condensing oligolysine to
siRNA; however, low electrostatic binding between the two
components, due to siRNA size and oligolysine surface charge,44
resulted in incomplete complexation (Figure S2, Supporting
Figure 1. Viability of (A) human neuroblastoma (SHEP) cells, (B) human liver hepatocellular carcinoma (HepG2) cells, (C) human lung cancer
(H460) cells, and (D) normal human fetal lung (MRC5) cells after incubation with P(MAA-co-CMA) copolymers of A-2% CMA, A-4% CMA, and
A-8% CMA along with P(MAA) (A-0% CMA) for 72 h, measured with AlamarBlue assay. The assay was repeated three times in five replicates, and the
viability results were normalized according to the positive control (untreated cells). Error bars represent standard deviation (P < 0.05).
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Information). Alternatively, DNA (13.1 kb) was utilized for
ternary complexation assays. Binary complexes formed between
the positive rich domains of oligolysine and negatively charged
phosphate backbones of DNA, were prepared at N/P ratios
ranging from 0.5:1 to 4:1, each complex corresponding to 50 ng
DNA (Figure S3, Supporting Information). Complete retarda-
tion (absence of naked DNA bands) was observed in lanes 7−10,
indicating binary complexation N/P ratios to be 1.5:1 and over.
Ternary complexes were formed by fixing the phosphate/
carboxylate (P/C) ratio of DNA to P(MAA-co-CMA) at 1:1
(50 ng), while increasing the amine ratio (N) of oligolysine from
0.5 to 50 (25 ng to 2.5 μg) (Figure 3A). It was predicted that
increasing the amine groups in the complex would intensify the
interactions among the binary complex and P(MAA-co-CMA);
therefore exhibit complexation ratios higher than 1.5:1 (binary
complexation).45 Overall stable polyelectrolyte complexes
incorporating DNA and oligolysine were formed with N/P/C
ratios of 4:1:1, 4:1:1, and 6:1:1 for A-2% CMA, A-4% CMA and
A-8% CMA, respectively. The higher complexation ratio, seen in
A-8% CMA, is due to the higher amount of cholesterol groups
hindering the carboxylic acid groups and obstructing their ionic
interactions with the amine units (of oligolysine), thus driving the
complexation ratio to higherN/P/Cvalues to achieve full conjugation.
Q-P(DMAEMA-co-CMA)-siRNA polyelectrolyte complex
formation was based on spontaneous electrostatic interactions
between the cationic amine units (present in the cationic
polymer) and anionic phosphate groups (seen on the siRNA
phosphate backbone). A representative gel is shown in Figure 3B
where Q-20% CMA is conjugated to siRNA (5 pmol; phosphate
molar ratio fixed at 1) at varying N/P ratios from 2:1 to 30:1.
Complete gel retardation (absence of free siRNA bands) for
Q-20%CMA-siRNAwas achieved at 8:1 and above.With increasing
amounts of amine units (decreasing CMAmoieties), themobility of
siRNA retarded at lower N/P ratios resulting from either size
change in the complex, neutralization of the anionic groups or
simpler complexation in the absence of hindrance caused by CMA
units.46 The siRNA complexation ratios for Q-2% CMA, Q-4%
CMA, Q-8% CMA, Q-15% CMA and Q-20% CMA copolymers
were revealed as 4:1, 6:1, 6:1, 6:1 and 8:1 respectively, which are
comparable results to previous DMAEMA reports.23,47,48 The
decreasing amount of protonable amine groups in the polymer
composition, from Q-2% CMA to Q-20% CMA, drove the
complexation ratios to slightly higher N/P values in order to attain
complete conjugation.
Overall gel electrophoresis illustrated the minimum charge
ratios necessary for full complexation of P(MAA-co-CMA)-
oligolysine-DNA and Q-P(DMAEMA-co-CMA)-siRNA conju-
gate series. However, the ideal N/P ratios, which demonstrate
the greatest transfection efficiency and lowest cell toxicity, tend
to be higher than the minimum charge ratio.3,47 Preliminary
studies, conducted via flow cytometry, revealed the optimal N/P
ratios for ternary complexes [(P(MAA-co-CMA)-oligolysine-
DNA) and Q-P(DMAEMA-co-CMA)-siRNA complex series] to
range between 6:1:1 to 50:1:1, and 20:1 to 150:1, respectively.
Characterization of Polyelectrolyte Complexes: Size,
Surface Charge, and Stability Analysis. Transfection
Figure 2. Viability of (A) human neuroblastoma (SHEP) cells, (B) human liver hepatocellular carcinoma (HepG2) cells, (C) human lung cancer
(H460) cells and (D) normal human fetal lung (MRC5) cells after incubation with Q-P(DMAEMA-co-CMA) copolymers that consist of 2%, 4%, 8%,
15% and 20% CMA along with Q-P(DMAEMA) (Q-0% CMA) for 72 h, measured with Alamar Blue assay. The assay was repeated three times in five
replicates, and the viability results were normalized according to the positive control (untreated cells). Error bars represent standard deviation
(P < 0.05).
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efficiency is strongly influenced by properties such as polyplex
size and ζ potential.49 Accordingly, P(MAA-co-CMA)-oligoly-
sine-DNA and Q-P(DMAEMA-co-CMA)-siRNA complexes
were characterized for their particle size, surface charge and
hydrodynamic stability via dynamic light scattering.
Prior to P(MAA-co-CMA)-oligolysine-DNA ternary complex
investigations, binary complexes (oligolysine-DNA) prepared at
N/P ratios of 6:1, 12:1 and 50:1 were analyzed for their mean
diameters (Figure S4A, Supporting Information) Earlier studies
conducted on oligolysine-DNA condensation revealed the
existence of a ‘critical oligolysine concentration’ which represents
the minimum amount of oligolysine necessary for creating stable
complexes. Above the ‘critical concentration’ threshold (>6:1)
the light scattering intensity of the complexes remained constant
resulting in similar hydrodynamic diameters, as seen in
Supporting Information, Figure S4A (54.2 ± 2.6 nm (N/P
6:1), 60.2 ± 2.0 nm (N/P 12:1), 60.7 ± 1.8 nm (N/P 50:1)).50
Nevertheless, the addition of P(MAA-co-CMA) copolymers
enhanced the overall size of the ternary complexes from 60.2 ±
5.6 nm to 69.4± 2.6 for A-2% CMA, 75.7± 0.6 nm to 91.6± 2.3
nm for A-4% CMA and 82.1± 2.2 nm to 94.6± 1.5 nm for A-8%
CMA with increasing amine conjugation ratios (Table 1).
Complexes prepared with A-2%CMA, displayed amore compact
structure owing its complexation behavior being mostly driven
Scheme 1. Formation of (A) P(MAA-co-CMA)-oligolysine-DNA Ternary Complexes and (B) Q-P(DMAEMA-co-CMA)-siRNA
Binary Complexes
Figure 3. Agarose gel electrophoresis of (A) oligolysine/DNA/A-2% CMA polymer complexes (B) Q-20% CMA polymer: siRNA conjugates prepared
at varying amine/phosphate/carboxylate (N/P/C) ratios and N/P ratios, respectively. (A) 0.8% Agarose gel: Lane 1: EasyLadder II, Lane 2: Naked
DNA, Lane 3: Naked oligolysine, Lane 4: Naked A-2% CMA, Lanes 5−12: ternary complexes at N/P/C ratios from 0.5:1:1 to 50:1:1. (B) 2% Agarose
gel: Lane 1: HyperLadder II, Lane 2: Naked siRNA, Lane 3: Naked Q-20% CMA, Lanes 4−10: binary conjugates at N/P ratios of 2:1 to 30:1.
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by the methacrylic acid subunits. While A-8% CMA complexes
formed bigger molecules as its conjugation was influence by
bulky, cholesterol subunits.
Ternary complexes prepared with P(MAA-co-CMA) copoly-
mer series exhibited a similar zeta potential pattern where
complexes of 6:1:1, 12:1:1 and 50:1:1 N/P/C ratios were all
positively charged (Table 1 and Figure S4B, Supporting
Information). Complexes with overall cationic charge are more
susceptible to cellular internalization owing to their attraction
toward the negatively charged plasma membrane.22,51 The zeta
potential of A-2% CMA complexes displayed charge values of
22.3 mV (6:1:1), 23.1 mV (12:1:1) and 27.9 mV (50:1:1). This
increase in zeta potential can be attributed to the addition of
amine units (from 6 to 50) in the final complex. Charge values for
complexes of A-4% CMA and A-8% CMA displayed the same
trend; ranging from 21.8 mV to 30.8 mV and 32.3 mV to 37.2 mV,
respectively. The differences in the intensity of zeta potential
between P(MAA-co-CMA) series is credited to the organization of
the copolymers in solution state. Copolymer compositions with
increasing CMA units tend to form supramolecular structures,
where lipid moieties are brought together exposing the charged
molecules on the outer layer.31 Additionally, with decreasingMAA
moieties in the copolymer composition, fewer acidic groups
occupy the oligolysine amine units triggering the complexes to
exhibit overall higher surface charges.
Table 2 represents the diameter and ζ-potential of
Q-P(DMAEMA-co-CMA)-siRNA complexes prepared at N/P
20:1 ratio in aqueous solution. The effective diameter of
complexes increased from 41.7 ± 4.8 nm to 72.5 ± 3.7 nm as
the CMA ratio changed from 2 to 20%. Concurring with previous
findings52 and P(MAA-co-CMA)-oligolysine-DNA ternary com-
plexes, the particle size of Q-P(DMAEMA-co-CMA) gene
vectors increased proportionally with the bulky hydrophobic
cholesterol content in the copolymers, ensuing Q-20%
CMA-siRNA complexes to exhibit the largest size at N/P 20:1
ratio. The ζ-potential of Q-P(DMAEMA-co-CMA)-siRNA
complex series (20:1) showed a slight reduction with increasing
cholesterol units (decreasing DMAEMA entities) once again
verifying the charge influence of the amine content and the
shielding effect of CMA moieties on the copolymer.53
Increasing the cationic density of complexes typically enhances
the cellular uptake and gene transfection efficiency.51,54 Thus
complexes with higher N/P ratios (>20:1) were prepared to
examine the change in their size and ζ properties. Polyelectrolyte
formation with copolymers comprising Q-2%, Q-4% and Q-8%
CMA (high amine content), at N/P ratios greater than 20:1,
enhanced the cationic charge density of the particle but was
predicted to promote toxicity (in line with IC50 values). In
contrast, Q-15% and Q-20% CMA copolymers (with lower
surface charge) required higher amounts of polymers per nucleic
acid condensation thus permitting complexation ratios up to 150:1
to be utilized without causing severe toxicity. Consequently
representative Q-20% CMA-siRNA polyplexes were further
examined with N/P ratios ranging from 50:1 to 150:1 in Table 3.
The complex diameters decreased with increasing complexation
N/P ratios owing to the enhancement in charge ratios which
elevated the electrostatic forces between polyelectrolyte and siRNA.
The cationic ζ-potential of Q-20% CMA-siRNA polyplexes at 50:1
N/P ratios showed a slim increase in comparison to N/P 150:1.
Complexes, which are formed on the basis of electrostatic
interactions, have the tendency to shrink, aggregate and/or
produce larger supramolecular structures progressively with
time.55 P(MAA-co-CMA)-oligolysine-DNA complexes formed
at N/P/C ratios of at 6:1:1 displayed similar diameters, among
each P(MAA-co-CMA) series, throughout time portraying
characteristics of stable particles (Figure 4A). Moreover,
polyelectrolyte complexes of 12:1:1 (N/P/C ratio) illustrated a
steady trend in the first hour; however, fluctuations in the 90th
minute resulted in minor decreases in the hydrodynamic
diameters (Figure 4B). With the highest conjugation ratio of
50:1:1 ternary complexes revealed size enlargement within the
hour (Figure 4C). Over time the complexes formed unstable
aggregates with reducing diameters; which was expected as
highly charged cationic polyplexes are quite susceptible to
collapse and form unstable particles in aqueous suspensions.56
PDI data (Table S4, Supporting Information) obtained from
DLS verify the stability of complexes prepared at 6:1:1 and 12:1:1
ratio along with the unsteadiness of 50:1:1 complexes overtime.
The stability profile of Q-P(DMAEMA-co-CMA)-siRNA
series at varying complexation ratios were examined in OptiMeM
within 20 min intervals for 2 h (Figure 5). Polyelectrolyte
complexes formed at N/P ratios of 20:1 exhibited a steady trend
overtime with minimal fluctuations (±8.4 nm) in their
hydrodynamic diameter overall portraying features of stable
particles (Figure 5A). At higher N/P ratios Q-20% CMA-siRNA
complexes formed particles smaller particles which demon-
strated steady diameters for the first 80 to 100 min.
In summary, results indicate that the hydrodynamic diameter
and zeta potential of the polyplexes are immensely influenced by
the CMA ratio in the polymer composition (increasing in size
with increasing CMA units) and the quantity of charge species
Table 1. Size and ζ-Potential Measurements of P(MAA-co-
CMA)-oligolysine-DNA Complexes at Varying N/P/C Ratios
N/P/C ratio polymer composition diameter (nm) ζ-potential (mV)
6:1:1 A-2% CMA 60.2 ± 5.6 22.3 ± 0.9
A-4% CMA 75.7 ± 0.6 21.7 ± 0.3
A-8% CMA 82.1 ± 2.2 32.3 ± 1.1
12:1:1 A-2% CMA 62.6 ± 2.3 23.1 ± 1.9
A-4% CMA 74.5 ± 1.1 30.7 ± 1.1
A-8% CMA 82.9 ± 2.1 38.2 ± 0.7
50:1:1 A-2% CMA 69.4 ± 2.6 27.9 ± 1.6
A-4% CMA 91.6 ± 2.3 30.8 ± 1.5
A-8% CMA 94.6 ± 1.5 37.2 ± 1.0
Table 2. Size and ζ-Potential Measurements of Q-
P(DMAEMA-co-CMA)-siRNA Complexes at N/P Ratio of
20:1
polymer composition diameter (nm) ζ-potential (mV)
Q-2% CMA 41.7 ± 4.8 64.4 ± 0.8
Q-4% CMA 45.8 ± 2.1 60.6 ± 0.9
Q-8% CMA 51.9 ± 1.7 51.0 ± 1.3
Q-15% CMA 57.0 ± 3.4 46.1 ± 1.4
Q-20% CMA 72.5 ± 3.7 48.9 ± 1.2
Table 3. Size and ζ-Potential Measurements of Q-20% CMA-
siRNA Complexes at Varying N/P Ratios
N/P ratios diameter (nm) ζ-potential (mV)
Q-20% CMA (50:1) 54.4 ± 1.7 55.6 ± 1.2
Q-20% CMA (100:1) 51.2 ± 1.4 58.1 ± 1.6
Q-20% CMA (150:1) 49.3 ± 2.4 59.7 ± 1.2
Biomacromolecules Article
dx.doi.org/10.1021/bm4013088 | Biomacromolecules 2013, 14, 4135−41494141
covering the complex surface (increasing charge with increasing
protonable amines). Owing to their efficient size (<100 nm) and
cationic surface charge, P(MAA-co-CMA)-oligolysine-DNA and
Q-P(DMAEMA-co-CMA)-siRNA complex series are both
plausible candidates for overcoming cellular barriers and
effectively entering cells.57 However, fluctuations in P(MAA-
co-CMA)-oligolysine-DNA complexes stability, diminishes
their use in in vivo therapy. Conversely the stability profile of
Q-P(DMAEMA-co-CMA)-siRNA polyplexes offers the siRNA a
longer in vivo half-life than free siRNA component, as siRNA
would degrade instantly in its free form.58 Stable polyplexes like
these, with diameters less than 100 nm, are plausible candidates
for passive tumor targeting via the enhanced permeability and
retention (EPR) effect.59−61 The EPR effect relies on enhanced
vascular permeability and reduced lymphatic drainage of
capillaries surrounding the tumors which trigger the accumu-
lation of macromolecules to the tumor sites.58,59 Accordingly,
untargeted stable complexes are more susceptible to bypass the
healthy tissues, as they would be easily removed by lymphatic
drainage, and gather in the pathological sites affected with leaky
vasculature (like inflammation and tumor areas) and enhance
therapeutic delivery to those sites.62 Overall the compact size,
high cationic nature and stability profile of these Q-
P(DMAEMA-co-CMA)-siRNA polyplexes hold potential for
enhancing therapeutic delivery in in vivo cancer cells.
In vitro Gene Transfection Studies. The transfection
efficacy of P(MAA-co-CMA)-oligolysine-DNAandQ-P(DMAEMA-
co-CMA)-GFP siRNA complexes were evaluated via various analysis
techniques (RT-qPCR, western, flow cytometry) in SHEP and
GFP expressing SHEP cells, respectively.
SHEP cells transfected with P(MAA-co-CMA)-oligolysine-
DNA complexes prepared with GFP expressing (pmaxFP-
GreenC) plasmids (2 μg/mL) for 72 h were analyzed byWestern
blotting and flow cytometry for GFP protein quantification and
fluorescence intensity, respectively. Post-72 h treatments protein
extracts were gathered from samples and quantified by western
analysis. The protein of interest, GFP, along with the house
keeping protein, GAPDH, bands were distinguished with
suitable antibodies, and measured by densitometry relative to
SHEP control (Figure 6A). Figure 6B displays the relative GFP
protein expression (%) attained by ternary complexes which
were prepared at various N/P/C ratios. P(MAA-co-CMA)-
oligolysine-DNA complexes demonstrated no more than 14%
GFP protein expression where the expression reduced with
increasing amine (N) charge ratio. DNA transfection via L2K
displayed 1.7-folds higher GFP expression than the ternary
complexes in SHEP cells. The ternary complexes transfection
efficiency determined by flow cytometry - showing <2.5% GFP
fluorescence intensity - is portrayed in Figure 6C in comparison
to L2K-DNA control. This discrepancy in results can be attributed
the difference between the two analysis techniques, as one is
quantifying protein (stable throughout measurements) and the
other is measuring fluorescence (may vary upon absorbing light).
The ternary complexes, with increasing oligolysine units,
displayed very low gene transfection efficacy in both protein and
fluorescence intensity levels. In line with gel retardation assays;
lysine polymers, one of the first cationic polymers used for gene
transfection,63 have shown efficient binding to DNA and
enhanced protection against nuclease degradation.64 However,
lysine polymers are prone to demonstrate nominal transfection
ability when applied alone, as they cannot facilitate or induce
endosomal release of DNA.65 Ternary systems were designed
with P(MAA-co-CMA) moieties in order to induce membrane
destabilization and overcome the setbacks associated with
oligolysine delivery. Although increased amounts of oligolysine
(overall cationic charge) may occupy the majority of the anionic
groups (associated to P(MAA-co-CMA)) thus prevent mem-
brane interactions from taking place. High levels of lysine
molecules overpower the P(MAA-co-CMA) units, obscuring
their membrane disruptive properties, ultimately causing the
system to perform as a binary-complex of oligolysine-DNA
instead; which is a system notorious for exhibiting nominal
transfection efficacy.55 In the case of protein quantification,
results suggested that increasing amine conjugation ratios from
(6:1:1) to (50:1:1) reduced the transfection efficiency from
roughly 14% to 4.5%. This can be attributed to the greater surface
charge triggering stronger electrostatic interactions with DNA
molecules, the formation of unstable aggregates (in line with
stability studies), and relative toxicity.66
In vitro transfection activity of Q-P(DMAEMA-co-CMA)-
siRNA complexes were evaluated in GFP-SHEP cells utilizing
anti-GFP siRNA (50 nM) against the gene of interest. Prior to
transfection assays; a time-lapse study (at 24, 48, 72, 96, 120 h)
was undertaken to evaluate the knockdown efficiency of the anti-GFP
siRNA sequence in GFP-SHEP cells using L2K (Figures S5−S7,
Supporting Information). The siRNA transfection activity, examined
at two different concentrations 50 nM and 100 nM, revealed the
maximal levels of GFP knockdown to occur at 48 h (for mRNA
knockdown) and 72 h (for protein and fluorescence intensity
suppression) time points. Accordingly the gene silencing efficiency of
polyplexes, mRNA expression levels in GFP-SHEP cells were
analyzed via RT-qPCR analysis at 48 h post-siRNA transfection.
Gene level suppression observed in GFP-SHEP cells was highly
Figure 4. The hydrodynamic stability of P(MAA-co-CMA)-oligolysine-
DNA complexes, in terms of aggregate formation, determined by
dynamic light scattering as a function of time. The diameter of
complexes prepared at N/P/C ratios of (A) 6:1:1, (B) 12:1:1 and (C)
50:1:1 in PBS (pH 7.4) at 37 °C.
Biomacromolecules Article
dx.doi.org/10.1021/bm4013088 | Biomacromolecules 2013, 14, 4135−41494142
dependent on polymer composition and the polyplex N/P ratio.
Copolymers comprising higher amine groups displayed greater
transfection efficiency at low N/P ratios (20:1) and higher rates of
toxicity at N/P 50:1 and over (Figure 7A,B). Copolymers with low
buffering capacity; Q-15% CMA and Q-20% CMA entailed higher
doses of polymers in their complex formulation (N ≥ 50), to
promote endosomal escape under the influence of the proton sponge
effect and further advance their transfection activity.67 Q-20% CMA-
siRNA polyplexes prepared at N/P ratio 150:1 demonstrated the
greatest gene silencing profile, in its series, owing to its increased
surface charge which promoted higher buffering capacity therefore
greater endo/lysosomal rupture. The delicate balance between the
hydrophobic and hydrophilic components of the polymer design
allows Q-20%CMA-siRNA polyplexes to be formed at N/P ratios as
high as 150:1 without projecting any toxicity toward the cells.54
The protein level inhibition achieved by Q-P(DMAEMA-co-
CMA)-siRNA complexes at varying N/P ratios for 72 h, are
illustrated in Figure 7C,D. The time lag between mRNA and
protein silencing is correlated to the half-lives of both
components, particularly the half-life of the proteins being
longer than its corresponding transcript.68 Similar to gene
knockdown studies, at these N/P 20:1 ratio, copolymers with
higher DMAEMA ratios demonstrated greater transfection
efficiency. Of the complexes, the highest protein knockdown was
achieved by copolymer Q-2% CMA (82.2%) having suppression
levels similar to L2K-siRNA (94.6%) and Q-P(DMAEMA)-siRNA
(90.0%) complexes. Upon increasing the N/P conjugation ratio to
50:1, copolymers Q-15% CMA and Q-20% CMA displayed higher
transfection profiles. The efficacy of Q-15% CMA increased by
1.8-folds when complexed at N/P 50:1; whereas Q-20% CMA-
siRNA complexes multiplied their protein knockdown efficiency at
N/P ratios 50:1 and over. The enhancement in polyplex transfection
activity is likely due to the increase in particle zeta potential which
enforces higher degrees of cellular binding and consequently greater
transfection.3,69 On the other hand Q-P(DMAEMA)-siRNA
(Q-0% CMA) polyplexes prepared at N/P ratios higher than 50:1
exhibited high toxicity (verified throughout imaging, protein and
gene quantification experiments), once again validating the
significance of CMA integration to the polymer chain. Cholesterol
introduces benefits by improving biocompatibility, facilitating
intracellular dissociation (by causing steric hindrance and triggering
less compact binding to payload) and assisting in membrane
interactions.54 Cholesterol-based systems have been utilized in a
number for studies for siRNA delivery both in vitro51,70 and in
vivo.54,71 Cationic lipid-based constructs are the most established
systems used for the systemic delivery of siRNA into the liver.72 The
liver comprises numerous siRNA targets such as hepatitis, fibrosis,
hepatocellular carcinoma and cholesterol biosynthesis.73 Thus,
studies investigating siRNA activity via cholesterol based-systems
have shown promising results in hepatocellular carcinoma cells
HepG2 and Huh-7 in vitro.71,74 In accordance with cell viability
resultspolymers illustrating higher IC50 values in HepG2 cells
Q-(DMAEMA-co-CMA) copolymer series are more likely to
exhibit higher levels of siRNA transfection if they were to be
analyzed in hepatocellular carcinoma cells.
Figure 7E,F illustrates the fluorescence intensity suppression
72 h after Q-P(PMAEMA-co-CMA)-siRNA transfection in
GFP-SHEP cells. All copolymers exhibited reasonable activity
Figure 5. Hydrodynamic stability of Q-P(DMAEMA-co-CMA)-siRNA complexes. Polyplex diameters were analyzed in OptiMeM by dynamic light
scattering as a function of time. (A) Q-P(DMAEMA-co-CMA)-siRNA complex series with an N/P ratio of 20:1 (Q-0% CMA as 0% (20:1), Q-2% CMA
as 2% (20:1), Q-4%CMA as 4% (20:1), Q-8%CMA as 8% (20:1), Q-15% CMA as 15% (20:1), Q-20% CMA as 20% (20:1)) (B) representative Q-20%
CMA-siRNA conjugates prepared at N/P ratios of 50:1 and 150:1 ((20% (50:1) and 20% (150:1)).
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in transfecting siRNA; however, highest suppression levels were
achieved by Q-2% CMA (70.0% GFP knockdown). The
transfection efficiency of copolymers at N/P ratio 20:1 followed
the order of Q-2%CMA (70.0%) >Q-4%CMA (68.4%) >Q-8%
CMA (63.0%) > Q-15% CMA (53.3%) > Q-20% CMA (35.9%).
The gradual decrease in transfection activity can be accounted for
by the increasing cholesterol units, in the copolymer composition,
which are known to shield the surface charge and cause steric
hindrance.69 Particle shielding counteracts interactions with the
cell surface and as a result can hinder the cellular uptake process
and reduce the transfection efficacy of the therapeutic
complex.53,75 Furthermore, copolymers with decreasing DMAE-
MA units (tertiary amine groups) display weaker siRNA binding
that may cause complex dissociation prior to cell internalization
and thus exhibit lower levels of gene silencing.53 The optimal
transfection activity mediated by Q-2% CMA (20:1) was
comparable to the gene silencing levels of both Q-P(DMAEMA)
(Q-0% CMA) and L2K. Q-2% CMA-siRNA complexes achieved
higher transfection values atN/P ratio of 20:1 in comparison to the
widely used control transfection regent; branched-poly-
(ethyleneimine) (bPEI)25,76(25000 g/mol) employed in MDA-
MB-435-GFP (human breast cancer cell line), NIH 3T3
(fibroblast cell line) and Neuro-2a (murine neuroblastoma cell
line), respectively. The representative histogram of flow cytometry
for Q-P(DMAEMA-co-CMA)-siRNA (20:1) series treatments is
shown in Figure S8, Supporting Information. The plot illustrates
GFP suppression in GFP-SHEP cells with a distinct shift to the
left; moving further away from the control with higher transfection
efficiency with decreasing cholesterol content. To achieve higher
levels of transfection, theN/P ratios ofQ-P(DMAEMA-co-CMA)-
siRNA conjugates were increased to 50:1, 100:1 and 150:1. With
increasing amine ratios complexes comprised higher levels of free
cationic DMAEMA groups that altered the viability and
transfection efficiency of the cells.67 While Q-2% CMA, Q-4%
CMA, and Q-8% CMA showed significant toxicity, Q-15% CMA
andQ-20%CMAdemonstrated adequate results. The transfection
efficiency of Q-20% CMA was enhanced from 35.9% to 44.2% at
the N/P ratio of 50:1 due to an increase in charge density,
electrostatic interactions and ultimately siRNA condensation.25,47
The fluorescence intensity, protein and gene knockdown profiles
of Q-20%CMA-siRNA complexes, prepared with N ≥ 50 amine
ratios, overall demonstrate efficient siRNA silencing without
inducing significant levels of toxicity. Due to nontoxic effects and
enhanced stability Q-20%CMA-siRNA complexes (N/P ≥ 50:1),
which are P(DMAEMA)-derived polyplexes well-known for their
long circulating properties,69 these systems have potential in vivo
applications.
Cellular Uptake Imaging Studies.The cellular distribution
profile of P(MAA-co-CMA)-oligolysine-DNA and Q-P(DMAEMA-
co-CMA)-siRNA complex series was investigated in SHEP cells
by confocal laser scanning microscopy (CLSM). L2K mediated
gene delivery illustrated in Figure S9A, Supporting Information
and Figure 8A was identified as positive control-images for SHEP
cells; due to the efficient gene delivery properties of L2K based
systems which exhibit reasonable levels of DNA uptake and
localize siRNA molecules in the cytoplasm.77
Ternary complexes comprising oligolysine, TUBB-pREP4
plasmid DNA (no fluorescence) and Alexa Fluor 488 labeled A-
8% CMA (green) copolymers were prepared at varying N/P/C
ratios (6:1:1, 12:1:1, 50:1:1) and incubated in cells for 5 h prior
to imaging. Alexa Fluor 488 labeled A-8%CMAwas generated by
tailoring small amounts of carboxylic molecules on the
copolymer into stable amide bonds that carry reactive dithiols
via EDC/sulfo-NHS reactions78 and labeling them with a
Figure 6. Transfection efficiency of polyelectrolyte complexes in vitro evaluation in SHEP cells (A) Representative immunoblot image of the post-72 h
P(MAA-co-CMA)-oligolysine-DNA (2 μg/mL DNA) transfection study. Upper band: GFP; lower band: GAPDH loading control. (B) Graphical
illustration of the quantitative analysis of relative GFP protein expression normalized to GAPDH loading control using untreated L2K-DNA cells as the
reference. (C) GFP fluorescence intensity expression results determined by flow cytometry of SHEP cells at 72 h post transfection with P(MAA-co-
CMA)-oligolysine-DNA complex series. Treatments include 2 μg/mLDNA delivery by L2K (positive control) and P(MAA-co-CMA)-oligolysine-DNA
complex series with N/P/C ratios of 6:1:1, 12:1:1 and 50:1:1. Controls comprise of untreated SHEP cells and L2K only treatments for 72 h. The data
represents the mean ± SD of three independent experiments (**P < 0.005, ***P < 0.0005 versus L2K-DNA).
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Figure 7.Transfection efficiency ofQ-P(DMAEMA-co-CMA)-siRNA complexes in GFP-SHEP cells with 50 nM anti-GFP siRNA at varyingN/P ratios.
Analysis of GFPmRNA expression by RT-qPCR following 48 h treatments of (A) L2K-siRNA (positive control) andQ-P(DMAEMA-co-CMA)-siRNA
polyplex series at N/P 20:1 ratio (Q-0% CMA-siRNA as Q-0% (20:1), Q-2% CMA-siRNA as Q-2% (20:1), Q-4% CMA-siRNA as Q-4% (20:1), Q-8%
CMA-siRNA as Q-8% (20:1), Q-15% CMA-siRNA as Q-15% (20:1), Q-20% CMA-siRNA as Q-20% (20:1)). (B) Q-P(DMAEMA-co-CMA)-siRNA
transfection study comprised of Q-15%CMA-siRNA (N/P ratio 50:1 as Q-15% (50:1)) andQ-20%CMA (N/P ratios of 50:1, 100:1, 150:1 shown as Q-
20% (50:1), Q-20% (100:1), Q-20% (150:1) respectively). All values were normalized to the housekeeping gene β2-microglobulin. GFP protein
suppression studies determined by Western blotting post 72 h polyplex treatments. (C) Representative immunoblot image and graphical illustration of
the relative GFP protein expression in GFP-SHEP cells after Q-P(DMAEMA-co-CMA)-siRNA complex (N/P 20:1) treatments. (D) A representative
Western blot for the transfection study of Q-15% CMA-siRNA (N/P ratio 50:1) and Q-20% CMA-siRNA (N/P ratios of 50:1, 100:1, 150:1) followed
by the quantitative analysis of GFP protein expression expressed as a normalized ratio to untreated GFP-SHEP cells. Upper band: GFP; lower band:
GAPDH loading control. GFP fluorescence intensity inhibition results determined by flow cytometry 72 h post transfection with Q-P(DMAEMA-co-
CMA) copolymer series at (E) N/P ratios of 20:1, (F) N/P ratios of 50:1 and 100:1 for Q-15% CMA-siRNA (as Q-15% (50:1), Q-15% (100:1)) and
N/P ratios of 50:1, 100:1 and 150:1 for Q-20% CMA. Controls comprise of untreated GFP-SHEP cells, L2K only, L2K-siRNA, untreated SHEP cells,
andQ-P(DMAEMA-co-CMA) series only treatments for 72 h. The data represents the mean± SD of three to four independent experiments (*P < 0.05,
**P < 0.005, ***P < 0.0005 versus L2K-siRNA).
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fluorescent maleimide dye. The Alexa Fluor dye content of the-
modified copolymer was found to be 0.22 mol %; which is
sufficient for effective detection by flow cytometry and confocal
microscopy analysis.79 Transfected DNA molecules along with
the cell nuclei were stained with 5 μM DRAQ5 nuclear dye
(magenta). Representative images of Alexa Fluor 488 labeled
A-8% CMA-oligolysine-DNA complexes prepared at 6:1:1
(N/P/C ratio) are displayed in Supporting Information,
Figure S9B,C for SHEP cells. In line with gel electrophoresis,
ternary complexation was similarly confirmed by confocal
microscopy, owing to the image layers of DNA molecules
(magenta) and Alexa Fluor 488 labeled-copolymers (green)
coinciding with each other at identical sites Notably, Alexa Fluor
488 labeled A-8% CMA-oligolysine-DNA complexes formed
small aggregates (indicated by arrows) adhering to the cell
surface and/or outside the cells. The assembly of aggregates can
be contributed to depletion of stability observed in complexes
over time (in agreement with DLS studies).48 While a few
conjugates were internalized (indicated by blue arrows) at 6:1:1
ratio, ternary complexes prepared at higher conjugation ratios
(50:1:1; larger aggregates) were merely stuck on the cell surface
owing to their enhanced surface charge (Figure S9 (D-E), Supporting
Information).
A control study investigating the cellular uptake profile of
binary complexes -comprising oligolysine and Alexa Fluor 488
labeled A-8% CMA- resulted in small aggregates and adhered to
the surface of the cells (Figure S10, Supporting Information).
The interactions between binary complexes and cells were
Figure 8. Confocal laser scanning microscopy exhibiting cell uptake of Q-P(DMAEMA-co-CMA)-siRNA conjugates in SHEP cells after 5 h of
incubation: (A) L2K-siRNA (50 nM) (control); (B) N/P (20:1) Q-2% CMA-siRNA (50 nM siRNA); (C) N/P (50:1) Q-20% CMA-siRNA (50 nM
siRNA); (D) N/P (100:1) Q-20% CMA-siRNA (50 nM siRNA); (E) N/P (200:1) Q-20% CMA-siRNA (25 nM siRNA). Nuclei are visualized with
Hoechst 33342 stain. Alexa Fluor 488-conjugated siRNAwas utilized for the assay, and fluorescent images were acquired at λex = 495 nm and λem = 591 nm.
Scale bars correspond to 10 μm.
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governed by nonspecific ionic interactions between the positive
complex and negatively charged cell surface. Lysine polyplexes
are usually equipped with ligands that facilitate cell uptake and
endosomal escape.80 However, the ionic interactions over-
powered the predicted hydrophobic interactions (between the
membrane and P(MAA-co-CMA) copolymers), resulting in
systems with only binding ability rather than cell internalization
capability.
Representative images of Q-P(DMAEMA-co-CMA) copoly-
mers (Q-2% CMA and Q-20% CMA) delivering 50 nM Alexa
Fluor 488 conjugated siRNA are shown in Figure 8 B,C. Strong
fluorescence signals were observed in the cytoplasm with Q-2%
CMA-siRNA complexes at their optimal N/P ratio 20:1. Trials
runs with Q-2% CMA-siRNA polyplexes at higher conjugation
ratios resulted in images of cells in distress due to the increased
number of unoccupied positive charges (free DMAEMA units)
which are prone to cause cell death.48,81
Q-20%CMA-siRNA polyplexes at N/P ratio of 50:1 uniformly
distributed siRNA throughout the cellular cytoplasm revealing
high transfection efficiency. Q-20% CMA-siRNA complexes
prepared with higher conjugation ratios (100:1 and 200:1)
demonstrated efficient internalization of siRNA to the cytoplasm
(Figure 8D,E). DMAEMA polymers tend to act as proton
sponges in endosomal pH, the tertiary amine groups trigger a
transition in their conformation which evidently raptures the
endosome.21,82 Overall images revealed that siRNA was well
dispersed in the cytoplasm and in line with their high transfection
efficiency indicating polyplex treatments successfully escaped the
endosomes.
In summary, the cell uptake profile of P(MAA-co-CMA)-
oligolysine-DNA and Q-P(DMAEMA-co-CMA)-siRNA com-
plex series demonstrated differing end-results. The delivery
issues -associated with Alexa Fluor 488 labeled A-8% CMA-
oligolysine-DNA ternary systems- elucidated by confocal
microscopy were consistent to those observed in the GFP
transfection studies. Their efficiency was limited due to the
system favoring ionic interactions, which facilitate strong binding
to negatively charged membrane surfaces, over interactions
through cholesterol units that can facilitate internalization.
Ultimately, this kind of behavior enforces interactions with charged
serum proteins in the circulation system and resulting in negligible
gene delivery levels, increased toxicity and rapid clearance from the
body.81 One possible method to inhibit aggregation and unwanted
interactions with in vivo serum components would be to integrate
stable biocompatible PEG molecules to the complex that could
reduce the challenging intramolecular interactions.37,83 Suitably, cell
uptake results, consistent with the gene knockdown studies,
revealed that Q-P(DMAEMA-co-CMA) copolymers are vastly
more effective at internalizing genes, escaping the endosomal-
lysosomal pathway and releasing their cargo (aka siRNA) into the
cytoplasm.
■ CONCLUSION
In conclusion, a library of CMA-derived ionic copolymers
composed of both biological and synthetic moieties with diverse
surface charges were evaluated for their therapeutic efficiency.
The cholesterol units in the copolymer composition were altered
to carefully tune the physicochemical properties and functions of
the biohybrid constructs. As predicted, incorporating cholesterol
entities into the cationic polymer chains reduced the overall
toxicity (in H460 and HepG2 cell lines), whereas in anionic
systems there was no significant toxicity regardless of CMA.
Therapeutic complexes (for siRNA and DNA) were prepared
purely on the basis of electrostatic interactions, resulting in
P(MAA-co-CMA)-oligolysine-DNA and Q-(P(DMAEMA-co-
CMA)-siRNA complexes at complexation ratios starting from
6:1:1 (N/P/C) and 20:1 (N/P), respectively. The hydro-
dynamic diameter, ζ potential and complex stability were
evaluated in accord with conjugation ratios and mol % of
cholesterol (present in the polymer composition). The
therapeutic efficiency of the polyplexes was assessed in SHEP
cells via transfection and imaging assays, illuminating the positive
and negative attributes of each therapeutic design. In the case of
anionic copolymers, ternary complexes exhibited hurdles with
gene delivery and were alternatively used for drug delivery
applications (future work). The increasing cholesterol content
throughout the Q-P(DMAEMA-co-CMA) copolymer series
enhanced the biocompatibility of the polyplexes (by reducing
toxicity with increasing CMA units in the composition), prompted
their membrane interactions, and enabled their intracellular
dissociation. The hydrophobic anchors also improved the stability
of the cationic copolymers in physiological conditions, ultimately
leading to an increase in the circulation time. Similar to in vivo-
jetPEI, cationic linear polymers instantly interacted with their
therapeutics (siRNA), forming positively charged polyplexes that
were efficiently internalized, while avoiding cargo degradation (via
proton sponge effect). The gene delivery (siRNAsilencing) profile of
Q-P(DMAEMA-co-CMA)-siRNA complexes, reported herein, sug-
gests that these positively charged, stable particles are promising
candidates for further in vivo investigations.
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